Sera Prognostics, Inc.

Sera Prognostics, Inc.

SERA·NASDAQ

$2.25

+9.5%
HealthcareMedical - Diagnostics & Research

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

At a Glance

Live Snapshot
Market Cap$85.74M
EPS-0.6700
P/E Ratio-3.35
Earnings Date08/05/2026

sera

Net Change in Cash

Last Annual Value

-99.00K

3-Year CAGR

85%

5-Year CAGR

58%

10-Year CAGR

%

Sera Prognostics, Inc.

Sera Prognostics, Inc. Competitors Analysis of Net Change in Cash

SERA · NASDAQ
CompanyNet Change in Cash
CAGR 3Y
CAGR 5Y
CAGR 10Y
-99.00K
N/AN/AN/A 
3.04M
N/A-54.1%N/A
-1.00K
N/AN/AN/A
-28.43M
N/AN/AN/A
DCGO logo
DocGo Inc.
NASDAQ:DCGO
-54.85M
N/AN/AN/A
-13.15M
N/AN/AN/A
3.68M
N/A-33.6%5.4%
-52.03M
N/AN/AN/A
-693.00K
N/AN/AN/A
12.35B
N/A196.9%N/A
-9.04M
N/AN/AN/A
Sera Prognostics, Inc.

Sera Prognostics, Inc. Fair Value Envelope

SERA · NASDAQ

Our analysis suggests that SERA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.245, this represents a potential HIDDEN relative to our calculated worth for Sera Prognostics, Inc..

Intrinsic Value
Current Price: $2.245